- Home
- CHRO vs TLPH Comparison
CHRO vs TLPH Comparison
Compare CHRO & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRO
- TLPH
- Stock Information
- Founded
- CHRO 2002
- TLPH 2005
- Country
- CHRO United States
- TLPH United States
- Employees
- CHRO N/A
- TLPH N/A
- Industry
- CHRO
- TLPH Biotechnology: Pharmaceutical Preparations
- Sector
- CHRO
- TLPH Health Care
- Exchange
- CHRO Nasdaq
- TLPH Nasdaq
- Market Cap
- CHRO 11.3M
- TLPH 12.7M
- IPO Year
- CHRO 2024
- TLPH 2011
- Fundamental
- Price
- CHRO $1.68
- TLPH $0.60
- Analyst Decision
- CHRO Strong Buy
- TLPH Strong Buy
- Analyst Count
- CHRO 1
- TLPH 2
- Target Price
- CHRO N/A
- TLPH $4.50
- AVG Volume (30 Days)
- CHRO 104.9K
- TLPH 69.0K
- Earning Date
- CHRO 03-04-2025
- TLPH 03-05-2025
- Dividend Yield
- CHRO N/A
- TLPH N/A
- EPS Growth
- CHRO N/A
- TLPH N/A
- EPS
- CHRO N/A
- TLPH N/A
- Revenue
- CHRO N/A
- TLPH $281,000.00
- Revenue This Year
- CHRO N/A
- TLPH N/A
- Revenue Next Year
- CHRO N/A
- TLPH N/A
- P/E Ratio
- CHRO N/A
- TLPH N/A
- Revenue Growth
- CHRO N/A
- TLPH N/A
- 52 Week Low
- CHRO $0.45
- TLPH $0.50
- 52 Week High
- CHRO $4.84
- TLPH $1.50
- Technical
- Relative Strength Index (RSI)
- CHRO 50.49
- TLPH 45.01
- Support Level
- CHRO $1.59
- TLPH $0.60
- Resistance Level
- CHRO $1.99
- TLPH $0.68
- Average True Range (ATR)
- CHRO 0.29
- TLPH 0.05
- MACD
- CHRO -0.06
- TLPH -0.00
- Stochastic Oscillator
- CHRO 41.44
- TLPH 28.93
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.